Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Test de l'ajout d'un médicament anticancéreux, ZEN003694, au traitement de chimiothérapie habituel (capécitabine) pour les cancers métastatiques ou non résécables

27 octobre 2026 mis à jour par: National Cancer Institute (NCI)

Essai de phase I de ZEN003694 (ZEN-3694) en association avec la capécitabine chez des patients atteints de tumeurs solides

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVE:

I. To determine the safety and tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) in combination with capecitabine in patients with solid tumors.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine.

II. To determine the pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine.

III. To determine the pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine (death receptor 5 [DR5] dynamics and apoptosis).

IV. To identify molecular subpopulations particularly sensitized to bromodomain and extra-terminal motif inhibitor (BETi) and capecitabine.

OUTLINE: This is a dose-escalation study of ZEN003694 and capecitabine, followed by a dose-expansion study.

Patients receive ZEN003694 orally (PO) once daily (QD) and capecitabine PO twice daily (BID) 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.

After completion of study treatment, patients are followed up for safety 30 days after the last dose, and then every 3 months for 12 months.

Type d'étude

Interventionnel

Inscription (Estimé)

30

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Irvine, California, États-Unis, 92612
        • Recrutement
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-827-8839
          • E-mail: ucstudy@uci.edu
        • Chercheur principal:
          • Fa-Chyi Lee
      • Orange, California, États-Unis, 92868
        • Recrutement
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-827-8839
          • E-mail: ucstudy@uci.edu
        • Chercheur principal:
          • Fa-Chyi Lee
    • Florida
      • Gainesville, Florida, États-Unis, 32610
        • Recrutement
        • UF Health Cancer Institute - Gainesville
        • Contact:
        • Chercheur principal:
          • Thomas J. George
    • Illinois
      • Shiloh, Illinois, États-Unis, 62269
        • Actif, ne recrute pas
        • Memorial Hospital East
    • Kansas
      • Fairway, Kansas, États-Unis, 66205
        • Recrutement
        • University of Kansas Clinical Research Center
        • Contact:
        • Chercheur principal:
          • Joaquina C. Baranda
      • Kansas City, Kansas, États-Unis, 66160
        • Recrutement
        • University of Kansas Cancer Center
        • Contact:
        • Chercheur principal:
          • Joaquina C. Baranda
      • Westwood, Kansas, États-Unis, 66205
        • Recrutement
        • University of Kansas Hospital-Westwood Cancer Center
        • Contact:
        • Chercheur principal:
          • Joaquina C. Baranda
    • Missouri
      • City of Saint Peters, Missouri, États-Unis, 63376
        • Actif, ne recrute pas
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, États-Unis, 63141
        • Actif, ne recrute pas
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, États-Unis, 63110
        • Actif, ne recrute pas
        • Washington University School of Medicine
      • St Louis, Missouri, États-Unis, 63129
        • Actif, ne recrute pas
        • Siteman Cancer Center-South County
      • St Louis, Missouri, États-Unis, 63136
        • Actif, ne recrute pas
        • Siteman Cancer Center at Christian Hospital
    • New York
      • New York, New York, États-Unis, 10032
        • Recrutement
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Chercheur principal:
          • Ryan Moy
        • Contact:
      • The Bronx, New York, États-Unis, 10461
        • Recrutement
        • Montefiore Medical Center-Einstein Campus
        • Contact:
        • Chercheur principal:
          • Chaoyuan Kuang
      • The Bronx, New York, États-Unis, 10467
        • Recrutement
        • Montefiore Medical Center - Moses Campus
        • Contact:
        • Chercheur principal:
          • Chaoyuan Kuang
      • The Bronx, New York, États-Unis, 10461
        • Recrutement
        • Montefiore Medical Center-Weiler Hospital
        • Contact:
        • Chercheur principal:
          • Chaoyuan Kuang
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
        • Recrutement
        • University of Cincinnati Cancer Center-UC Medical Center
        • Contact:
        • Chercheur principal:
          • Davendra P. Sohal
      • West Chester, Ohio, États-Unis, 45069
        • Recrutement
        • University of Cincinnati Cancer Center-West Chester
        • Contact:
        • Chercheur principal:
          • Davendra P. Sohal
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Chercheur principal:
          • Susanna V. Ulahannan
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15232
        • Recrutement
        • UPMC Hillman Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 412-647-8073
        • Chercheur principal:
          • Anwaar Saeed
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Recrutement
        • Vanderbilt University/Ingram Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-811-8480
        • Chercheur principal:
          • Thatcher R. Heumann
      • Nashville, Tennessee, États-Unis, 37204
        • Recrutement
        • Vanderbilt Breast Center at One Hundred Oaks
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-811-8480
        • Chercheur principal:
          • Thatcher R. Heumann

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Dose Escalation additional criteria: Patients must have histologically confirmed cancer that is metastatic or unresectable and must have progressed on standard therapies which would have included fluorouracil (5-FU) or capecitabine
  • Dose Escalation additional criteria specifically for colorectal cancer (CRC) patients: Willingness and ability to undergo a pre-treatment biopsy
  • Dose Expansion additional criteria: Patients must have histologically confirmed CRC that is metastatic or unresectable and must have progressed on standard therapies which would have included 5-FU or capecitabine
  • Dose Expansion additional criteria: Willingness and ability to undergo pre- and on- treatment biopsies
  • Patients must have measurable disease
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with capecitabine in patients < 18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky >= 60%)
  • Availability of archival tumor tissue at the time of patient enrollment for molecular profiling studies
  • Prior to study dosing, previous systemic therapy must have been completed for at least five half-lives or 2 weeks, whichever is shorter
  • Absolute neutrophil count >= 1,000/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
  • Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patients should be New York Heart Association Functional Classification of class 2B or better
  • The effects of ZEN003694 (ZEN-3694) and capecitabine on the developing human fetus are unknown. For this reason and because BET inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion Criteria:

  • Previous treatment with BET inhibitors
  • History of inability to tolerate capecitabine at the projected treatment dose on this trial
  • Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
  • Treatment for HIV, hepatitis B or hepatitis C only if this interferes with the current treatment (e.g. through drug-drug interactions)
  • Gastrointestinal pathology or history that adversely impacts the ability to take or absorb oral medication
  • Hepatic tumor burden > 30% or peritoneal carcinomatosis
  • Untreated/uncontrolled central nervous system (CNS) disease
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Severe intercurrent illness or comorbidity
  • Inability to comply with the protocol and/or not willing or who will not be available for follow-up assessments
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy up to and including grade 2
  • Patients who are receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or other agents used in study
  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors of CYP3A4 must be discontinued at least 7 days, and inducers 14 days prior to the first dose of ZEN003694 and capecitabine. Substrates of CYP1A2 with narrow therapeutic window must be avoided while taking ZEN003694
  • Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694). These potential risks may also apply to other agents used in this study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment (ZEN003694, capecitabine)

Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.

Undergo MRI

Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle

Undergo biopsy

Autres noms:
  • Bx
  • BIOPSIE_TYPE
  • Biopsie

Undergo collection of blood samples

Autres noms:
  • Collecte d'échantillons biologiques
  • Spécimen biologique collecté
  • Collecte de spécimens
  • Collection d'échantillons

Undergo PET/CT

Autres noms:
  • Imagerie médicale, Tomographie par émission de positrons
  • ANIMAUX
  • TEP-scan
  • Scan de tomographie par émission de positrons
  • Tomographie par émission de positrons
  • PT
  • Tomographie par émission de positrons (procédure)

Given PO

Autres noms:
  • Xeloda
  • Ro 09-1978/000

Given PO

Autres noms:
  • BETi ZEN-3694
  • ZEN 3694
  • ZEN-3694
  • ZEN003694

Undergo CT and PET/CT

Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of adverse events
Délai: Up to 30 days after last dose

Adverse events and serious adverse events will be tabulated for each dose levels. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.

Up to 30 days after last dose
Maximum tolerated dose (MTD)
Délai: During the first cycle of therapy (Cycles = 21 days)

Defined as the highest dose level with no more than 1/6 dose-limiting toxicity. Dose level 4 was selected as the MTD.

During the first cycle of therapy (Cycles = 21 days)
Recommended phase 2 dose (RP2D)
Délai: Up to 30 days after last dose

Dose level 4 was selected as the RP2D.

Up to 30 days after last dose

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine
Délai: Up to 12 months

Treatment response will be assessed for all patients based on Response Evaluation Criteria in Solid Tumors version 1.1: complete response (CR), partial response (PR), stable disease (SD), and progression of disease (PD). Clinical benefit rate is defined as the addition of CR, PR and SD.

Up to 12 months
Progression free survival (PFS)
Délai: Up to 12 months

PFS will be estimated by the Kaplan-Meier method, along with 95% confidence regions.

Up to 12 months
Objective response rate (ORR)
Délai: Up to 12 months

Defined as the addition of CR and PR. The probability of ORR and clinical benefit rate will be estimated with exact 95% binomial confidence intervals.

Up to 12 months
Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine
Délai: Up to 12 months

Will determine the PK of ZEN003694 (ZEN-3694) in combination with capecitabine. Capecitabine PK will be evaluated in the absence and presence of ZEN003694 (ZEN-3694) and Cmax and area under curve (AUC) will be compared with a paired test. ZEN003694 (ZEN-3694) PK will be evaluated in the presence of capecitabine and Cmax and AUC will be compared descriptively with historical data.

Up to 12 months
Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine
Délai: Up to 12 months

Will determine PD of ZEN003694 (ZEN-3694) in combination with capecitabine. Ribonucleic acid sequencing of death receptor 5 (DR5). DR5 is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. Apoptosis by Pharmacodynamic Assay Development and Implementation Section (PADIS) lab. Panel 3 is priority, but other panels will be evaluated with remaining lysate. Apoptosis is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05.

Up to 12 months
Molecular subpopulations particularly sensitized to BETi and capecitabine
Délai: Up to 12 months

Will identify molecular subpopulations particularly sensitized to BETi and capecitabine. Based on WES of archival tissue, we will evaluate descriptively any mutations in genes relevant to DNA damage repair, signaling and (fluoropyrimidine) metabolism, any relations with peculiar response and/or toxicity.

Up to 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Anwaar Saeed, University of Pittsburgh Cancer Institute LAO

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

8 novembre 2023

Achèvement primaire (Estimé)

30 juin 2027

Achèvement de l'étude (Estimé)

30 juin 2027

Dates d'inscription aux études

Première soumission

6 avril 2023

Première soumission répondant aux critères de contrôle qualité

6 avril 2023

Première publication (Réel)

7 avril 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner